TISSIUM CEO’s Vision Is To Make The Tissue Recon Label Stick
CEO Bancel Envisages TISSIUM As A Tissue Reconstruction Specialist Rather Than Simply A Provider Of A Technology
Christophe Bancel, CEO of French medtech innovator TISSIUM, has made a career in various parts of the health care products industry, identifying business opportunities, founding, directing and leading ventures, and planning for contingencies. The ex-Serono and UCB executive, who has had many other postings, is now testing his adaptability and leadership qualities by bringing a versatile class III synthetic polymer device into key markets.
You may also be interested in...
The devices regulator has sought private sector input in updating AR/VR guidelines, but needs to do more on telemedicine integration. Mixed experiences are reported on UDI and the new IVD regulation.
Health care delivery has been transformed over the past decade, and so has Royal Philips, whose CEO Frans van Houten explains why both were necessary, and the extra impetus for system-wide change following the COVID-19 pandemic.
Fit For The Future: Industry Gets Involved As UK Medtech And Digital Health Care Regulation Reaches Turning Point
The MHRA is in listening mode as it gathers feedback to shape the UKCA marking for medical devices. That, and how the agency precisely will oversee UK device regulation in the future, are front of mind for industry.